Chimeric Antigen Receptor T Cells in Hematologic Malignancies.

Area of Science:

• Oncology
• Immunotherapy
• Hematology

Background:

• B-cell hematologic malignancies resistant to chemotherapy have poor prognoses.
• Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy offers a promising treatment option for relapsed or refractory disease.

Purpose of the Study:

• To review the efficacy and safety of CAR T-cell therapy in B-cell malignancies.
• To highlight the importance of managing treatment-related toxicities, particularly cytokine release syndrome (CRS).

Main Methods:

• Review of early clinical trial data for CAR T-cell therapy.
• Analysis of conditioning regimens used prior to CAR T-cell infusion.
• Examination of CAR T-cell therapy-associated toxicities and their management strategies.

Main Results:

• CAR T-cell therapy demonstrates promising results in patients with relapsed/refractory disease.
• Lymphodepleting conditioning regimens enhance T-cell expansion.
• Cytokine release syndrome (CRS) is a major, potentially life-threatening toxicity requiring rapid intervention.
• Tocilizumab is effective in managing severe CRS, allowing steroid use for refractory cases.
• Other toxicities include neutropenia, infection, tumor lysis syndrome, and neurotoxicity.

Conclusions:

• CAR T-cell therapy is a viable option for patients with relapsed/refractory B-cell malignancies.
• Proactive management of CRS and other toxicities is essential for optimizing patient outcomes.
• Ongoing research aims to refine patient selection, preparation, safety, and long-term management of CAR T-cell therapy.